BMP‑9 is a novel marker for colorectal tumorigenesis undergoing the normal mucosa‑adenoma‑adenocarcinoma sequence and is associated with colorectal cancer prognosis

Fan,Yinjie; Guo,Lingxiang; Zheng,Huachuan; Ji,Chunyong; Wang,Wenbin; Sun,Hongzhi

doi:10.3892/ol.2019.11125

BMP‑9 is a novel marker for colorectal tumorigenesis undergoing the normal mucosa‑adenoma‑adenocarcinoma sequence and is associated with colorectal cancer prognosis

Authors:
- Yinjie Fan
- Lingxiang Guo
- Huachuan Zheng
- Chunyong Ji
- Wenbin Wang
- Hongzhi Sun
View Affiliations

Affiliations: Department of General Surgery, The Affiliated Zhengzhou Central Hospital of Zhengzhou University, Zhengzhou, Henan 450007, P.R. China, Department of Experimental Oncology and Animal Center, Shengjing Hospital of China Medical University, Shenyang, Liaoning 110004, P.R. China, Department of Surgery, The First Affiliated Hospital of Jinzhou Medical University, Jinzhou, Liaoning 121001, P.R. China
Published online on: November 19, 2019 https://doi.org/10.3892/ol.2019.11125
Pages: 271-282
Copyright: © Fan et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Depending on the type of cancer, bone morphogenetic protein‑9 (BMP‑9) can promote or inhibit tumorigenesis; however, the function of BMP‑9 in colorectal cancer remains unclear. The aim of the present study was to evaluate the clinicopathological importance of BMP‑9 expression in the tumorigenesis of normal colorectal epithelial tissue, and subsequent transformation into adenoma and carcinoma. In addition, the present study aimed to determine the prognostic value of BMP‑9 on the survival of patients with colorectal cancer (CRC). A total of 65 patients with pathologically confirmed colorectal adenocarcinoma and a history of adenoma were enrolled. BMP‑9 and Ki‑67 expression was assessed retrospectively using paraffin‑embedded samples of normal colorectal mucosa, colorectal adenoma and CRC obtained from each patient. The prognostic value of BMP‑9 expression was analyzed in a group comprising 48 patients with CRC and a mean follow‑up duration of 39.1 months. Bioinformatics analyses were performed in order to validate the results of the present study using published CRC datasets. The results from the present study suggested that the expression of BMP‑9 gradually increased during the transition from normal mucosa to adenoma and subsequent adenocarcinoma (P<0.05); however, no significant association between the expression levels of BMP‑9 and the clinicopathological parameters of patients was reported. Kaplan‑Meier analysis revealed that patients with high expression levels of BMP‑9 exhibited shorter overall survival rate than those with low levels of expression (54.7 vs. 41.3 months; log‑rank test, P<0.05). Furthermore, regardless of tumor location and the presence of blood vessel tumor emboli, the univariate and multivariate analyses indicated that BMP‑9 expression may be an independent prognostic factor for the overall survival rate of patients with CRC. The results of the present study suggested that BMP‑9 may serve an oncogenic role and possess prognostic value in CRC.

View Figures

View References

1	Siegel RL, Miller KD and Jemal A: Cancer statistics, 2019. CA Cancer J Clin. 69:7–34. 2019. View Article : Google Scholar : PubMed/NCBI
2	Siegel RL, Miller KD, Fedewa SA, Ahnen DJ, Meester RGS, Barzi A and Jemal A: Colorectal cancer statistics, 2017. CA Cancer J Clin. 67:177–193. 2017. View Article : Google Scholar : PubMed/NCBI
3	Fearon ER and Vogelstein B: A genetic model for colorectal tumorigenesis. Cell. 61:759–767. 1990. View Article : Google Scholar : PubMed/NCBI
4	Vincent MD: Cancer: Beyond speciation. Adv Cancer Res. 112:283–350. 2011. View Article : Google Scholar : PubMed/NCBI
5	Terzić J, Grivennikov S, Karin E and Karin M: Inflammation and colon cancer. Gastroenterology. 138:2101–2114. 2010. View Article : Google Scholar : PubMed/NCBI
6	Yokoyama Y, Watanabe T, Tamura Y, Hashizume Y, Miyazono K and Ehata S: Autocrine BMP-4 signaling is a therapeutic target in colorectal cancer. Cancer Res. 77:4026–4038. 2017. View Article : Google Scholar : PubMed/NCBI
7	Miyazono K, Kamiya Y and Morikawa M: Bone morphogenetic protein receptors and signal transduction. J Biochem. 147:35–51. 2010. View Article : Google Scholar : PubMed/NCBI
8	Zhang Y, Chen X, Qiao M, Zhang BQ, Wang N, Zhang Z, Liao Z, Zeng L, Deng Y, Deng F, et al: Bone morphogenetic protein 2 inhibits the proliferation and growth of human colorectal cancer cells. Oncol Rep. 32:1013–1020. 2014. View Article : Google Scholar : PubMed/NCBI
9	Chen D, Zhao M, Harris SE and Mi Z: Signal transduction and biological functions of bone morphogenetic proteins. Front Biosci. 9:349–358. 2004. View Article : Google Scholar : PubMed/NCBI
10	Celeste AJ: Bone morphogenetic protein-9, a new member of the TGF-β superfamily. J Bone Miner Res. 1(9): S1361994.
11	Wagner DO, Sieber C, Bhushan R, Börgermann JH, Graf D and Knaus P: BMPs: From bone to body morphogenetic proteins. Sci Signal. 3:mr12010.PubMed/NCBI
12	Plouhinec JL, Zakin L and De Robertis EM: Systems control of BMP morphogen flow in vertebrate embryos. Curr Opin Genet Dev. 21:696–703. 2011. View Article : Google Scholar : PubMed/NCBI
13	Reddi AH and Reddi A: Bone morphogenetic proteins (BMPs): From morphogens to metabologens. Cytokine Growth Factor Rev. 20:341–342. 2009. View Article : Google Scholar : PubMed/NCBI
14	Ploemacher RE, Engels LJ, Mayen AE, Thies S and Neben S: Bone morphogenetic protein 9 is a potent synergistic factor for murine hemopoietic progenitor cell generation and colony formation in serum-free cultures. Leukemia. 13:428–437. 1999. View Article : Google Scholar : PubMed/NCBI
15	Helm GA, Alden TD, Beres EJ, Hudson SB, Das S, Engh JA, Pittman DD, Kerns KM and Kallmes DF: Use of bone morphogenetic protein-9 gene therapy to induce spinal arthrodesis in the rodent. J Neurosurg. 92 (Suppl):S191–S196. 2000.
16	Lopez-Coviella I, Berse B, Krauss R, Thies RS and Blusztajn JK: Induction and maintenance of the neuronal cholinergic phenotype in the central nervous system by BMP-9. Science. 28:313–316. 2000. View Article : Google Scholar
17	Chen C, Grzegorzewski KJ, Barash S, Zhao Q, Schneider H, Wang Q, Singh M, Pukac L, Bell AC, Duan R, et al: An integrated functionalgenomics screening program reveals a role for BMP-9 in glucose homeostasis. Nat Biotechnol. 21:294–301. 2003. View Article : Google Scholar : PubMed/NCBI
18	Truksa J, Peng HF, Lee P and Beutler E: Bone morphogenetic proteins 2, 4, and 9 stimulate murine hepcidin 1 expression independently of Hfe, transferrin receptor 2 (Tfr2), and IL-6. Proc Natl Acad Sci USA. 103:10289–10293. 2006. View Article : Google Scholar : PubMed/NCBI
19	David L, Mallet C, Mazerbourg S, Feige JJ and Bailly S: Identification of BMP9 and BMP10 as functional activators of the orphan activin receptor-like kinase 1 (ALK1) in endothelial cells. Blood. 109:1953–1961. 2007. View Article : Google Scholar : PubMed/NCBI
20	Na KY, Kim HS, Lee SK, Jung WW, Sung JY, Kim YW and Park YK: Papillary thyroid carcinoma with bone formation. Pathol Res Pract. 209:14–18. 2013. View Article : Google Scholar : PubMed/NCBI
21	Herrera B, van Dinther M, Ten Dijke P and Inman GJ: Autocrine bone morphogenetic protein-9 signals through activin receptor-like kinase-2/Smad1/Smad4 to promote ovarian cancer cell proliferation. Cancer Res. 69:9254–9262. 2009. View Article : Google Scholar : PubMed/NCBI
22	Herrera B, García-Álvaro M, Cruz S, Walsh P, Fernández M, Roncero C, Fabregat I, Sánchez A and Inman GJ: BMP9 is a proliferative and survival factor for human hepatocellular carcinoma cells. PLoS One. 8:e695352013. View Article : Google Scholar : PubMed/NCBI
23	Li Q, Gu X, Weng H, Ghafoory S, Liu Y, Feng T, Dzieran J, Li L, Ilkavets I and Kruithof-de Julio M: Bone morphogenetic protein-9 induces epithelial to mesenchymal transition in hepatocellular carcinoma cells. Cancer Sci. 104:398–408. 2013. View Article : Google Scholar : PubMed/NCBI
24	Ye L, Kynaston H and Jiang WG: Bone morphogenetic protein-9 induces apoptosis in prostate cancer cells, the role of prostate apoptosis response-4. Mol Cancer Res. 6:1594–1606. 2008. View Article : Google Scholar : PubMed/NCBI
25	Olsen OE, Wader KF, Misund K, Våtsveen TK, Rø TB, Mylin AK, Turesson I, Størdal BF, Moen SH, Standal T, et al: Bone morphogenetic protein-9 suppresses growth of myeloma cells by signaling through ALK2 but is inhibited by endoglin. Blood Cancer J. 4:e1962014. View Article : Google Scholar : PubMed/NCBI
26	Wan S, Liu Y, Weng Y, Wang W, Ren W, Fei C, Chen Y, Zhang Z, Wang T, Wang J, et al: BMP9 regulates cross-talk between breast cancer cells and bone marrow-derived mesenchymal stem cells. Cell Oncol (Dordr). 37:363–375. 2014. View Article : Google Scholar : PubMed/NCBI
27	Ren W, Liu Y, Wan S, Fei C, Wang W, Chen Y, Zhang Z, Wang T, Wang J, Zhou L, et al: BMP9 inhibits proliferation and metastasis of HER2-positive SK-BR-3 breast cancer cells through ERK1/2 and PI3K/AKT pathways. PLoS One. 9:e968162014. View Article : Google Scholar : PubMed/NCBI
28	Ren W, Sun X, Wang K, Feng H, Liu Y, Fei C, Wan S, Wang W, Luo J, Shi Q, et al: BMP9 inhibits the bone metastasis of breast cancer cells by downregulating CCN2 (connective tissue growth factor, CTGF) expression. Mol Biol Rep. 41:1373–1383. 2014. View Article : Google Scholar : PubMed/NCBI
29	America Joint Committee on Cancer, . The 7th edition of the AJCC cancer staging manual. 7th. New York: Springer; 2010
30	Edge SB and Compton CC: The American joint committee on cancer: The 7th edition of the AJCC cancer staging manual and the future of TNM. Ann Surg Oncol. 17:1471–1474. 2010. View Article : Google Scholar : PubMed/NCBI
31	Sarma DP: Dukes' classification of rectal cancer. South Med J. 81:407–408. 1988. View Article : Google Scholar : PubMed/NCBI
32	Kurashina K, Yamashita Y, Ueno T, Koinuma K, Ohashi J, Horie H, Miyakura Y, Hamada T, Haruta H, Hatanaka H, et al: Chromosome copy number analysis in screening for prognosis- related genomic regions in colorectal carcinoma. Cancer Sci. 99:1835–1840. 2008. View Article : Google Scholar : PubMed/NCBI
33	Gaedcke J, Grade M, Jung K, Camps J, Jo P, Emons G, Gehoff A, Sax U, Schirmer M, Becker H, et al: Mutated KRAS results in overexpression of DUSP4, a MAP-kinase phosphatase, and SMYD3, a histone methyltransferase, in rectal carcinomas. Genes Chromosomes Cancer. 49:1024–1034. 2010. View Article : Google Scholar : PubMed/NCBI
34	Muto T, Bussey HJ and Morson BC: The evolution of cancer of the colon and rectum. Cancer. 36:2251–2270. 1975. View Article : Google Scholar : PubMed/NCBI
35	Kinzler KW and Vogelstein B: Lessons from hereditary colorectal cancer. Cell. 87:159–170. 1996. View Article : Google Scholar : PubMed/NCBI
36	Herrera B, Dooley S and Breitkopf-Heinlein K: Potential roles of bone morphogenetic protein (BMP)-9 in human liver diseases. Int J Mol Sci. 15:5199–5220. 2014. View Article : Google Scholar : PubMed/NCBI
37	Astrologo L, Zoni E, Karkampouna S, Gray PC, Klima I, Grosjean J, Goumans MJ, Hawinkels LJAC, van der Pluijm G, Spahn M, et al: ALK1Fc Suppresses the human prostate cancer growth in in vitro and in vivo preclinical models. Front Cell Dev Biol. 5:1042017. View Article : Google Scholar : PubMed/NCBI
38	Lv Z, Yang D, Li J, Hu M, Luo M, Zhan X, Song P, Liu C, Bai H, Li B, et al: Bone morphogenetic protein 9 overexpression reduces osteosarcoma cell migration and invasion. Mol Cells. 36:119–126. 2013. View Article : Google Scholar : PubMed/NCBI
39	Hardwick JC, Kodach LL, Offerhaus GJ and van den Brink GR: Bone morphogenetic protein signalling in colorectal cancer. Nat Rev Cancer. 8:806–812. 2008. View Article : Google Scholar : PubMed/NCBI
40	Allaire JM, Roy SA, Ouellet C, Lemieux É, Jones C, Paquet M, Boudreau F and Perreault N: Bmp signaling in colonic mesenchyme regulates stromal microenvironment and protects from polyposis initiation. Int J Cancer. 138:2700–2712. 2016. View Article : Google Scholar : PubMed/NCBI
41	Voorneveld PW, Kodach LL, Jacobs RJ, van Noesel CJ, Peppelenbosch MP, Korkmaz KS, Molendijk I, Dekker E, Morreau H, van Pelt GW, et al: The BMP pathway either enhances or inhibits the Wnt pathway depending on the SMAD4 and p53 status in CRC. Br J Cancer. 112:122–130. 2015. View Article : Google Scholar : PubMed/NCBI
42	Howe JR, Bair JL, Sayed MG, Anderson ME, Mitros FA, Petersen GM, Velculescu VE, Traverso G and Vogelstein B: Germline mutations of the gene encoding bone morphogenetic protein receptor 1A in juvenile polyposis. Nat Genet. 28:184–187. 2001. View Article : Google Scholar : PubMed/NCBI
43	Davis H, Raja E, Miyazono K, Tsubakihara Y and Moustakas A: Mechanisms of action of bone morphogenetic proteins in cancer. Cytokine Growth Factor Rev. 27:81–92. 2016. View Article : Google Scholar : PubMed/NCBI
44	Loh K, Chia JA, Greco S, Cozzi SJ, Buttenshaw RL, Bond CE, Simms LA, Pike T, Young JP, Jass JR, et al: Bone morphogenetic protein 3 inactivation is an early and frequent event in colorectal cancer development. Genes Chromosomes Cancer. 47:449–460. 2008. View Article : Google Scholar : PubMed/NCBI
45	Yuan SX, Wang DX, Wu QX, Ren CM, Li Y, Chen QZ, Zeng YH, Shao Y, Yang JQ, Bai Y, et al: BMP9/p38 MAPK is essential for the antiproliferative effect of resveratrol on human colon cancer. Oncol Rep. 35:939–947. 2016. View Article : Google Scholar : PubMed/NCBI
46	Lorente-Trigos A, Varnat F, Melotti A, Ruiz I and Altaba A: BMP signaling promotes the growth of primary human colon carcinomas in vivo. J Mol Cell Biol. 2:318–332. 2010. View Article : Google Scholar : PubMed/NCBI
47	Sanjuan X, Fernández PL, Castells A, Castronovo V, van den Brule F, Liu FT, Cardesa A and Campo E: Differential expression of galectin 3 and galectin 1 in colorectal cancer progression. Gastroenterology. 113:1906–1915. 1997. View Article : Google Scholar : PubMed/NCBI
48	Miyata Y, Watanabe S, Sagara Y, Mitsunari K, Matsuo T, Ohba K and Sakai H: High expression of HuR in cytoplasm, but not nuclei, is associated with malignant aggressiveness and prognosis in bladder cancer. PLoS One. 8:e590952013. View Article : Google Scholar : PubMed/NCBI
49	Steinke-Lange V and Holinski-Feder E: Genetic screening and personalized prevention in colorectal cancer. Visc Med. 35:226–230. 2019. View Article : Google Scholar : PubMed/NCBI
50	De Roock W, De Vriendt V, Normanno N, Ciardiello F and Tejpar S: KRAS, BRAF, PIK3CA, and PTEN mutations: Implications for targeted therapies in metastatic colorectal cancer. Lancet Oncol. 12:594–603. 2011. View Article : Google Scholar : PubMed/NCBI
51	Yoshimatsu Y, Lee YG, Akatsu Y, Taguchi L, Suzuki HI, Cunha SI, Maruyama K, Suzuki Y, Yamazaki T, Katsura A, et al: Bone morphogenetic protein-9 inhibits lymphatic vessel formation via activin receptor-like kinase 1 during development and cancer progression. Proc Natl Acad Sci USA. 110:18940–18945. 2013. View Article : Google Scholar : PubMed/NCBI
52	Cunha SI and Pietras K: ALK1 as an emerging target for antiangiogenic therapy of cancer. Blood. 117:6999–7006. 2011. View Article : Google Scholar : PubMed/NCBI